PPTA Twitter

PlasmaProteins
PlasmaProteins Amy Efantis, President & CEO of @PlasmaProteins is grateful for all plasma donors and plasma collectors. Read more here: bit.ly/2N4ExoU pic.twitter.com/rWLUcZ9COe
4 days ago.
PlasmaProteins
PlasmaProteins “Ultimately, what drives my colleagues on the Board, my company, and the staff at PPTA is a focus on patients...” Karen Etchberger, of @CSLBehring , reflects on her election as Chair of @plasmaproteins Global Board of Directors. bit.ly/2u61VeZ pic.twitter.com/QKhDPwL1e0
4 days ago.

PPTA Co-Sponsors Public Workshop

On Sept. 17-18, 2015, PPTA co-sponsored a U.S. Food and Drug Administration (FDA) public workshop, New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins, with the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute and the National Hemophilia Foundation, on the NIH campus in Bethesda, Maryland, USA.

The workshop focused on genetic determinants of immunogenicity, uses of genetic information, preclinical assessments of immunogenicity, studies of previously untreated patients, and immune tolerance induction, and followed a European Medicines Agency workshop on hemophilia registries on July 1-2, 2015, in London, UK. The workshop agenda was developed by a steering committee comprised of the co-sponsors (including PPTA) and other stakeholders, and included presentations and panel discussions by PPTA, member and non-member companies, regulators, patient advocates, and clinicians.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100